Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: RJMC who wrote (3780)	12/19/2000 12:33:38 AM
From: TI2, TechInvestorToo	Read Replies (1) \| Respond to of 5665

Bob, Just reposting nuggetts from the bull. The following is a summary of a 33 page Adam Harkness report which I can forward upon request. Thanks TI2 AHH summary by TB 1. 1-2 more partnerships by June 01 not including the one we are expecting at any time 2. Approximatly 160 mabs in development, of which 67 are currently in the clinic. The number of mabs in the clinic in the next 10 years is expected to grow considerably driven primarily by the genomics efforts. Where do you think IMGN fits into the picture? 3. 22 Potential Cancer indications applicable to the TAP technology(US Only). The chart sites 1,092,480 cases of cancer that TAPS might target. 4.AHH revenue model does not take into account fast track status. Lots of revenue projections. I prefer the Stephens INC or Cowens report. 5. IMGN to operate at or near break even(at a minimum) as the company develops proprietary products. 6. Results from Chicago will probably be made available at ASCO May 12-15 2001. Basically, all the analysts reports to date say that IMGN is EXTREMELY UNDERVALUED COMPARED T0 other platform companies such as ABGX, MEDX, PDLI, Cambridge Antibody Technology company. tb